Bristol-Myers Squibb (BMS) is driving innovative actions in the bio-tech market across different dimensions. The company is making a big move in selling its psoriasis drug at an over
80% discount to some US patients and has launched its new direct-to-patient platform, leveraging immunology drug
Sotyktu. BMS is also considering strengthening its
passive income portfolios following its recent slide. The company's middle trial endpoint addition has secured a
phase 3 win in multiple myeloma and is planning to introduce schizophrenia drug
Cobenfy in the UK, matching the US price. Although some wealth and asset management firms have reduced their stake in BMS, its
commitment to the Veeva Vault CRM and the decision to sell a 60% stake in its China joint venture hint at strategic realignment moves. BMS is also expanding patient options with its Direct-to-Patient platform and has discovered new
TLR7 agonists. However, the
Current market trend shows some losses for the company, but with it plans to sell plaque psoriasis drug for over 80% discount starting in 2026, BMS's restructuring program could help boost its earnings growth.
Bristol-Myers Squibb News Analytics from Mon, 03 Feb 2025 08:00:00 GMT to Sun, 28 Sep 2025 01:07:00 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -2
